Stock of the Day

IQVIA (IQV)

$191.18

+$1.78 (+0.9%)

Market Cap: $32.49B

About IQVIA

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

IQVIA Bull Case

Here are some ways that investors could benefit from investing in IQVIA Holdings Inc.:

• The current stock price is around $190, which may present a buying opportunity for investors looking for growth in the healthcare analytics sector.
• IQVIA Holdings Inc. reported a strong earnings performance recently, with earnings per share (EPS) of $2.81, surpassing analysts' expectations, indicating robust financial health.
• The company has shown a year-over-year revenue increase of 5.3%, suggesting a positive growth trajectory and resilience in its business model.
• With a market capitalization of approximately $32.05 billion, IQVIA Holdings Inc. is a significant player in the life sciences industry, which may attract institutional investors.
• The stock has received a majority of buy ratings from analysts, reflecting confidence in its future performance and potential for appreciation.

IQVIA Bear Case

Investors should be bearish about investing in IQVIA Holdings Inc. for these reasons:

• The company has a relatively high debt-to-equity ratio of 2.45, which may indicate financial risk and reliance on debt for growth.
• IQVIA Holdings Inc. has a quick ratio of 0.84, suggesting potential liquidity issues, as it may not have enough short-term assets to cover its short-term liabilities.
• Recent trading volume was significantly lower than its average, which could indicate reduced investor interest or confidence in the stock.
• Analysts have varying price targets, with some suggesting a decrease from previous highs, which may create uncertainty about future stock performance.
• The stock's beta of 1.30 indicates higher volatility compared to the market, which could lead to greater risk for investors during market fluctuations.

Recent News

• 1 Cash-Producing Stock for Long-Term Investors and 2 We Question (msn.com)
• Thermo Fisher, ICU Medical, CONMED, Pediatrix Medical Group, and IQVIA Stocks Trade Up, What You Need To Know (msn.com)
• IQVIA Holdings (IQV) Enters Partnership With Kexing Biopharm To Enhance Drug Development (finance.yahoo.com)
• Lupin gains after launching Glucagon for Injection in U.S. market (msn.com)
• Viatris wins FDA nod for generic iron sucrose injection targeting Daiichi’s Venofer (msn.com)
• Zydus Lifesciences gets USDFA approval for Prucalopride tablets (msn.com)
• Kexing Biopharm Enters Strategic Partnership with IQVIA to Accelerate Global Expansion (finanznachrichten.de)